Soleno Therapeutics to Participate in Upcoming June Conferences
Soleno Therapeutics (NASDAQ: SLNO), a biopharmaceutical company focused on rare disease therapeutics, has announced its participation in two major healthcare conferences in June 2025:
- Jefferies Global Healthcare Conference: Corporate presentation scheduled for Wednesday, June 4, 2025, at 10:30 AM ET
- Goldman Sachs 46th Healthcare Conference: Corporate presentation scheduled for Tuesday, June 10, 2025, at 8:40 AM ET
Both presentations will be available for replay in the Investors section of Soleno's website.
Soleno Therapeutics (NASDAQ: SLNO), un'azienda biofarmaceutica specializzata in terapie per malattie rare, ha annunciato la sua partecipazione a due importanti conferenze nel settore sanitario a giugno 2025:
- Jefferies Global Healthcare Conference: presentazione aziendale prevista per mercoledì 4 giugno 2025 alle 10:30 ET
- Goldman Sachs 46th Healthcare Conference: presentazione aziendale prevista per martedì 10 giugno 2025 alle 8:40 ET
Entrambe le presentazioni saranno disponibili in replica nella sezione Investitori del sito web di Soleno.
Soleno Therapeutics (NASDAQ: SLNO), una compañía biofarmacéutica enfocada en terapias para enfermedades raras, ha anunciado su participación en dos importantes conferencias de salud en junio de 2025:
- Jefferies Global Healthcare Conference: presentación corporativa programada para el miércoles 4 de junio de 2025 a las 10:30 AM ET
- Goldman Sachs 46th Healthcare Conference: presentación corporativa programada para el martes 10 de junio de 2025 a las 8:40 AM ET
Ambas presentaciones estarán disponibles para reproducción en la sección de Inversores del sitio web de Soleno.
Soleno Therapeutics (NASDAQ: SLNO)는 희귀 질환 치료제에 중점을 둔 생명공학 회사로, 2025년 6월에 열리는 두 개의 주요 헬스케어 컨퍼런스에 참여할 예정임을 발표했습니다:
- Jefferies Global Healthcare Conference: 2025년 6월 4일 수요일 오전 10시 30분(동부시간) 예정된 기업 프레젠테이션
- Goldman Sachs 46th Healthcare Conference: 2025년 6월 10일 화요일 오전 8시 40분(동부시간) 예정된 기업 프레젠테이션
두 프레젠테이션 모두 Soleno 웹사이트의 투자자 섹션에서 다시보기로 제공될 예정입니다.
Soleno Therapeutics (NASDAQ : SLNO), une société biopharmaceutique spécialisée dans les traitements des maladies rares, a annoncé sa participation à deux grandes conférences de santé en juin 2025 :
- Jefferies Global Healthcare Conference : présentation d'entreprise prévue le mercredi 4 juin 2025 à 10h30 ET
- Goldman Sachs 46th Healthcare Conference : présentation d'entreprise prévue le mardi 10 juin 2025 à 8h40 ET
Les deux présentations seront disponibles en replay dans la section Investisseurs du site web de Soleno.
Soleno Therapeutics (NASDAQ: SLNO), ein biopharmazeutisches Unternehmen, das sich auf Therapien für seltene Krankheiten spezialisiert hat, hat seine Teilnahme an zwei wichtigen Gesundheitskonferenzen im Juni 2025 angekündigt:
- Jefferies Global Healthcare Conference: Unternehmenspräsentation am Mittwoch, den 4. Juni 2025, um 10:30 Uhr ET
- Goldman Sachs 46th Healthcare Conference: Unternehmenspräsentation am Dienstag, den 10. Juni 2025, um 8:40 Uhr ET
Beide Präsentationen werden im Bereich für Investoren auf der Website von Soleno als Wiederholung verfügbar sein.
- None.
- None.
REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in June:
Jefferies Global Healthcare Conference
Presentation Date: Wednesday, June 4, 2025 at 10:30 AM ET
Presentation Format: Corporate Presentation
Webcast: Here
Goldman Sachs 46th Healthcare Conference
Presentation Date: Tuesday, June 10, 2025 at 8:40 AM ET
Presentation Format: Corporate Presentation
Webcast: Here
A replay of both events will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
When is Soleno Therapeutics (SLNO) presenting at the Jefferies Global Healthcare Conference in 2025?
What time is Soleno Therapeutics' presentation at the Goldman Sachs Healthcare Conference in June 2025?
Where can investors access the replay of Soleno Therapeutics' June 2025 conference presentations?
What type of company is Soleno Therapeutics (SLNO)?
